OverviewSuggest Edit

Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company's products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

TypePublic
Founded2006
HQBedford, US
Websiteocutx.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Mar 2019)167(+41%)
Job Openings52
Revenue (FY, 2018)$2 M(+4%)
Share Price (Mar 2019)$3.9 (-5%)

Key People/Management at Ocular Therapeutix

Antony Mattessich

Antony Mattessich

CEO
Fred Khosravi

Fred Khosravi

Co - Founder, Director & Chairman
Show more

Ocular Therapeutix Office Locations

Ocular Therapeutix has an office in Bedford
Bedford, US (HQ)
36 Crosby Dr
Show all (1)
Report incorrect company information

Ocular Therapeutix Financials and Metrics

Ocular Therapeutix Revenue

Ocular Therapeutix's revenue was reported to be $1.99 m in FY, 2018
USD

Revenue (FY, 2018)

2.0m

Net income (FY, 2018)

(60.0m)

EBIT (FY, 2018)

(59.1m)

Market capitalization (22-Mar-2019)

168.8m

Closing stock price (22-Mar-2019)

3.9

Cash (31-Dec-2018)

54.1m
Ocular Therapeutix's current market capitalization is $168.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

772.0k1.8m1.9m1.9m2.0m

Revenue growth, %

127%

Sales and marketing expense

3.9m6.7m17.0m4.9m

General and administrative expense

9.2m11.0m15.5m18.8m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

97.0k143.0k458.0k441.0k477.0k475.0k438.0k523.0k340.0k648.0k498.0k

Cost of goods sold

20.0k32.0k80.0k153.0k115.0k

Gross profit

77.0k111.0k260.0k495.0k383.0k

Gross profit Margin, %

79%78%76%76%77%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

37.4m30.8m32.9m41.5m54.1m

Accounts Receivable

329.0k193.0k250.0k226.0k201.0k

Inventories

893.0k1.6m1.4m122.0k217.0k

Current Assets

76.2m107.0m69.9m43.3m56.2m
Quarterly
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(28.6m)(39.7m)(44.7m)(63.4m)(60.0m)

Depreciation and Amortization

547.0k754.0k881.0k1.6m2.3m

Inventories

(36.0k)(53.0k)924.0k(9.0k)(95.0k)

Accounts Payable

507.0k348.0k(159.0k)932.0k(796.0k)
USDY, 2018

Revenue/Employee

16.7k

Financial Leverage

2 x
Show all financial metrics
Report incorrect company information

Ocular Therapeutix News and Updates

Allergic Conjunctivitis Market Is Booming Worldwide | Nicox Pharma - Allergan, Aldeyra Therapeutics - Valeant, ORA, Novartis, Ocular Therapeutix, Pfizer, Santen Pharma

Allergic conjunctivitis is an eye inflammation caused by an allergic reaction to substances like pollen or mold spores. The inside of your eyelids and the covering of your eyeball have a membrane called the conjunctiva. Posted via Industry Today. Follow us on Twitter @IndustryToday

Retinal Drugs And Biologics Market 2019: Booming Worldwide by Key Players like Alimera Sciences, Janssen Biotech, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, Ocular Therapeutix, Inc.

The retina is a delicate and sensitive part of the human eye. It is helpful in processing and receiving the light and converts them into neural signals and passes them to the brain for the activities that are done visually. The retinal health disorders include age-related macular degeneration, infec…

Ocular Therapeutix stock drops 10% after FDA warning letter

Ocular Therapeutix Inc. shares dropped 10% in Friday premarket trade after the company said it received a warning letter from the U.S. Food and Drug Administration relating to the company's "compliance with data collection and information reporting obligations" for a study. The reporting obligation…

Glaucoma Treatment Global Market 2018: Key Players – Novartis, Pfizer, Allergan, Merck, Ocular Therapeutix

Wiseguyreports.Com adds “Glaucoma Treatment Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Unable to head off the FDA, Ocular Therapeutix gets second CRL for eye drug

Manufacturing has for the second time stepped on Ocular Therapeutix’s chance of an FDA approval for its new drug for pain following eye surgery.
Report incorrect company information

Ocular Therapeutix Frequently Asked Questions

  • When was Ocular Therapeutix founded?

    Ocular Therapeutix was founded in 2006.

  • Who are Ocular Therapeutix key executives?

    Ocular Therapeutix's key executives are Antony Mattessich and Fred Khosravi.

  • How many employees does Ocular Therapeutix have?

    Ocular Therapeutix has 167 employees.

  • What is Ocular Therapeutix revenue?

    Latest Ocular Therapeutix annual revenue is $2 m.

  • What is Ocular Therapeutix revenue per employee?

    Latest Ocular Therapeutix revenue per employee is $11.9 k.

  • Who are Ocular Therapeutix competitors?

    Competitors of Ocular Therapeutix include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.

  • Where is Ocular Therapeutix headquarters?

    Ocular Therapeutix headquarters is located at 36 Crosby Dr, Bedford.

  • Where are Ocular Therapeutix offices?

    Ocular Therapeutix has an office in Bedford.

  • How many offices does Ocular Therapeutix have?

    Ocular Therapeutix has 1 office.